These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 33758121)

  • 21. Impact of myocardial ischemia on myocardial revascularization in stable ischemic heart disease. Lessons from the COURAGE and FAME 2 trials.
    Torosoff MT; Sidhu MS; Boden WE
    Herz; 2013 Jun; 38(4):382-6. PubMed ID: 23695652
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Strategies in stable ischemic heart disease: lessons from the COURAGE and BARI-2D trials.
    Fernandez SF; Boden WE
    Curr Atheroscler Rep; 2010 Nov; 12(6):423-31. PubMed ID: 20845088
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Design and Rationale of the RIPCORD 2 Trial (Does Routine Pressure Wire Assessment Influence Management Strategy at Coronary Angiography for Diagnosis of Chest Pain?): A Randomized Controlled Trial to Compare Routine Pressure Wire Assessment With Conventional Angiography in the Management of Patients With Coronary Artery Disease.
    Elguindy M; Stables R; Nicholas Z; Kemp I; Curzen N
    Circ Cardiovasc Qual Outcomes; 2018 Feb; 11(2):e004191. PubMed ID: 29449442
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Percutaneous coronary intervention versus bypass surgery in patients with diabetes and multivessel coronary disease. Coronary revascularization after FREEDOM].
    Dörr R; Stumpf J; Dalibor J; Simonis G; Spitzer SG
    Herz; 2014 May; 39(3):331-42. PubMed ID: 24740094
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Optimal medical therapy with or without percutaneous coronary intervention to reduce ischemic burden: results from the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) trial nuclear substudy.
    Shaw LJ; Berman DS; Maron DJ; Mancini GB; Hayes SW; Hartigan PM; Weintraub WS; O'Rourke RA; Dada M; Spertus JA; Chaitman BR; Friedman J; Slomka P; Heller GV; Germano G; Gosselin G; Berger P; Kostuk WJ; Schwartz RG; Knudtson M; Veledar E; Bates ER; McCallister B; Teo KK; Boden WE;
    Circulation; 2008 Mar; 117(10):1283-91. PubMed ID: 18268144
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Rationale and design of the Fractional Flow Reserve versus Angiography for Multivessel Evaluation (FAME) 3 Trial: a comparison of fractional flow reserve-guided percutaneous coronary intervention and coronary artery bypass graft surgery in patients with multivessel coronary artery disease.
    Zimmermann FM; De Bruyne B; Pijls NH; Desai M; Oldroyd KG; Park SJ; Reardon MJ; Wendler O; Woo J; Yeung AC; Fearon WF
    Am Heart J; 2015 Oct; 170(4):619-626.e2. PubMed ID: 26386784
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Long-Term Clinical Outcomes Following Revascularization in High-Risk Coronary Anatomy Patients With Stable Ischemic Heart Disease.
    Bainey KR; Alemayehu W; Welsh RC; Kumar A; King SB; Kirtane AJ
    J Am Heart Assoc; 2021 Jan; 10(1):e018104. PubMed ID: 33342230
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Failed ISCHEMIA Trial or Failed Ischemia Testing?
    Dahal S; Budoff MJ
    J Invasive Cardiol; 2020 Apr; 32(4):E83-E85. PubMed ID: 32234969
    [TBL] [Abstract][Full Text] [Related]  

  • 29. After ISCHEMIA: Is cardiac MRI a reliable gatekeeper for invasive angiography and myocardial revascularization?
    Nagel E; Carerj ML; Arendt CT; Puntmann VO
    Herz; 2020 Aug; 45(5):446-452. PubMed ID: 32458013
    [TBL] [Abstract][Full Text] [Related]  

  • 30. After ISCHEMIA: is invasive physiology the only remaining gatekeeper for myocardial revascularization in chronic coronary syndromes?
    Kanoun S; Toth GG
    Herz; 2020 Aug; 45(5):453-457. PubMed ID: 32494947
    [TBL] [Abstract][Full Text] [Related]  

  • 31. From SYNTAX to FAME, a paradigm shift in revascularization strategies: the key role of fractional flow reserve in guiding myocardial revascularization.
    Mangiacapra F; Barbato E
    J Cardiovasc Med (Hagerstown); 2011 Aug; 12(8):538-42. PubMed ID: 21670702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Rational and design of the INtentional COronary revascularization versus conservative therapy in patients undergOing successful peripheRAl arTEry revascularization due to critical limb ischemia trial (INCORPORATE trial).
    Toth G; Brodmann M; Barbato E; Mangiacapra F; Schneller L; Orias V; Gil R; Bil J; Bartus S; Ruzsa Z
    Am Heart J; 2019 Aug; 214():107-112. PubMed ID: 31200280
    [TBL] [Abstract][Full Text] [Related]  

  • 33. International Study of Comparative Health Effectiveness with Medical and Invasive Approaches-Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design.
    Bangalore S; Maron DJ; Fleg JL; O'Brien SM; Herzog CA; Stone GW; Mark DB; Spertus JA; Alexander KP; Sidhu MS; Chertow GM; Boden WE; Hochman JS;
    Am Heart J; 2018 Nov; 205():42-52. PubMed ID: 30172098
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Application of Fractional Flow Reserve-Guided Percutaneous Coronary Intervention for Stable Coronary Artery Disease.
    Parikh V; Agnihotri K; Kadavath S; Patel NJ; Abbott JD
    Curr Cardiol Rep; 2016 Apr; 18(4):32. PubMed ID: 26915010
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ACC/AATS/AHA/ASE/ASNC/SCAI/SCCT/STS 2017 Appropriate Use Criteria for Coronary Revascularization in Patients With Stable Ischemic Heart Disease : A Report of the American College of Cardiology Appropriate Use Criteria Task Force, American Association for Thoracic Surgery, American Heart Association, American Society of Echocardiography, American Society of Nuclear Cardiology, Society for Cardiovascular Angiography and Interventions, Society of Cardiovascular Computed Tomography, and Society of Thoracic Surgeons.
    Patel MR; Calhoon JH; Dehmer GJ; Grantham JA; Maddox TM; Maron DJ; Smith PK
    J Nucl Cardiol; 2017 Oct; 24(5):1759-1792. PubMed ID: 28608183
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Should we be using fractional flow reserve more routinely to select stable coronary patients for percutaneous coronary intervention?
    Park SJ; Ahn JM
    Curr Opin Cardiol; 2012 Nov; 27(6):675-81. PubMed ID: 23044917
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Clinical Implications of the ISCHEMIA Trial: Invasive vs Conservative Approach in Stable Coronary Disease.
    Choudhary J; Chiu S; Bhugra P; Bikdeli B; Supariwala A; Jauhar R; Chatterjee S
    Curr Cardiol Rep; 2021 Mar; 23(5):43. PubMed ID: 33704597
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Application and clinical implications of revascularization on chronic coronary syndromes: From COURAGE to ISCHEMIA trial.
    Tsigkas G; Moulias A; Xaplanteris P; Bousoula E; Tzikas S; Toutouzas K; Davlouros P
    Hellenic J Cardiol; 2021; 62(6):447-451. PubMed ID: 33176210
    [No Abstract]   [Full Text] [Related]  

  • 39. Angiography-guided Multivessel Percutaneous Coronary Intervention Versus Ischemia-guided Percutaneous Coronary Intervention Versus Medical Therapy in the Management of Significant Disease in Non-Infarct-related Arteries in ST-Elevation Myocardial Infarction Patients With Multivessel Coronary Disease.
    Perera D; Crake T; Lee V
    Crit Pathw Cardiol; 2018 Jun; 17(2):77-82. PubMed ID: 29768315
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fractional flow reserve: an updated review.
    Elgendy IY; Conti CR; Bavry AA
    Clin Cardiol; 2014 Jun; 37(6):371-80. PubMed ID: 24652785
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.